News
Academy
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Latest Executive Roundtables
  • Asembia 2025
  • Sales Effectiveness
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe
Advertisement

News

Article

December 6, 2023

Top Health Trends On the Horizon in 2024

Author(s):

Don Tracy, Associate Editor

An overview of the nine biggest developments to expect across the healthcare industry in the year ahead.

Blue stethoscope and numbers 2024 on pastel background. The concept of health care in the New Year. Selective focus, copy space. Image Credit: Adobe Stock Images/ClareM

Image Credit: Adobe Stock Images/ClareM

Soaring healthcare costs, drug pricing transparency, and the upcoming US presidential election are among the top areas to watch in healthcare the upcoming year, according to an analysis by Business Group on Health . The report identified a total of nine specific areas to monitor in the coming year. According to the article, each trend relates to a part of employer health and well-being strategy, which may be impacted by broader factors, including the economy, the ongoing impact of the COVID-19 pandemic, regulation and compliance, technology and innovation, global trends, legislative actions, and workforce trends.1

First, it notes that health care costs are rising, with employers focusing more on costs and employee satisfaction. Heading into 2024, alarms have been raised for factors such as inflation, labor pressures on health care systems, concerns regarding provider shortages, increased mental health needs, missed and deferred preventive screenings that lead to more late-stage cancer diagnoses and worsening of chronic conditions.1

“To further complicate these dynamics, employees’ health care experiences are impacted by fragmentation and growing concerns about affordability of medications and medical services,” the authors wrote. “Furthermore, the growing number of effective but prohibitively expensive cell and gene therapies, along with projected high demand for and widespread use of GLP-1s for managing obesity, are emerging as material cost drivers for self-funded employers today, with the use of these treatments increasing in the coming years.”

Other key trends include:

Prioritizing access to mental health and substance use disorders. The authors cited a 2023 Gallup Poll that found depression rates are at an all-time high.

“To improve access, employers will focus on using virtual mental health providers, among other measures,” the authors wrote. “Furthermore, about a third of employers will offer on-site mental health services at a reduced cost. To ensure that employees’ needs are being met, there will also be a growing movement to hold vendors and partners accountable for expanding access.”

Employers are increasing their focus on preventative efforts for cancer and other serious conditions. This includes the introduction of enhanced screening options and refined cancer patient navigation processes.

“Biomarker screenings, pre-treatment genetic testing and cell/gene therapies represent opportunity if deployed appropriately and effectively,” the authors wrote. “Employers may increasingly look to these alternatives as a way to improve experience and outcomes.”

Employers raising concerns regarding drug pricing sustainability and transparency. The report notes that in terms of costs, the pharmacy trend is outpacing the overall health care trend, especially for specialty drugs as recent innovations in drug development have caused costs to soar ever higher.

“Without necessary transformation within the pharmaceutical market, employer plans—and the broader health care system—may crumble under the weight of unsustainable drug pricing,” the authors wrote. “Employers are increasingly demanding greater prescription drug pricing transparency from all parties.”

Heightened expectations on partners to deliver. The report predicts that many employers will be more discerning regading their partnerships and place a greater emphasis on accountability from their partners to deliver on the cost of services.

Global employers will focus on improving consistency across countries while taking into account local regulations and cultural appropriateness. Employers are expected to explore leading edge mechanisms, including captive insurance arrangements, to develop consistent programs across different regions worldwide.

A greater focus on well-being as a fundamental aspect of workforce strategy.

The report notes that many employers have moved beyond just physical health to incorporate mental health, financial well-being, social health, community and job satisfaction in their overall well-being strategies.

“As employers look ahead, they will need to balance their continued commitment to well-being against mounting cost pressures, potentially by investing in the highest priority and most highly valued initiatives,” the report authors wrote.

The impact of the upcoming US presidential election on healthcare. The fate of the Affordable Care Act, taxation of employer benefit plans, prescription drug pricing, affordability, provider consolidation, reproductive rights, transgender care, mental health, and health equity are among the top issues that could be affected by the results of the 2024 election.

An emphasis on preemption for self-insured employers as the Employee Retirement Income Security Act turns 50. The report notes that preemption allows employers to curate a consistent and equitable benefits package for employees and their families regardless of work location.1

“We live in a complex and interconnected world, and diverse factors impact employers as they seek to evolve benefit offerings for their workforces,” said Ellen Kelsay, president, CEO, Business Group on Health. “It will be increasingly important for their vendor partners to deliver in light of heightened expectations and accountability. Staying ahead of these trends will be paramount.”2

References

1. Trends to Watch in 2024. Business Group on Healthcare. November 28, 2023. Accessed December 4, 2023. https://www.businessgrouphealth.org/resources/trends-to-watch-in-2024

2. Rising Health Care Costs, Surging Prescription Drug Pricing, Acute Focus on Chronic Conditions Among 9 Trends to Watch in 2024, Says Business Group on Health. November 28, 2023. Accessed December 4, 2023. https://www.businessgrouphealth.org/en/newsroom/news-and-press-releases/press-releases/2024-trends-to-watch

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Related Content
Advertisement
CSL to Layoff 15% of Employees, Close 22 US-based Plasma Centers
August 22nd 2025

CSL to Layoff 15% of Employees, Close 22 US-based Plasma Centers

Don Tracy, Associate Editor
Cell and Gene Therapy Check-in 2024
August 22nd 2025

Cell and Gene Therapy Check-in 2024

Miranda Schmalfuhs
AbbVie Latest to Commit to New US Manufacturing Growth Projects, Committing $195 Million to Expand API Capabilities
August 22nd 2025

AbbVie Latest to Commit to New US Manufacturing Growth Projects, Committing $195 Million to Expand API Capabilities

Don Tracy, Associate Editor
Industry Outlook 2022
August 22nd 2025

Industry Outlook 2022

Elaine Quilici Miranda Schmalfuhs
Stephanie J. Creary, Assistant Professor of Management at The Wharton School of The University of Pennsylvania.
August 22nd 2025

How Should BioPharma C-Suites Guide and Support Remaining Employees After Workforce Reductions?

Michael Wong
Merck to Cut 6,000 Jobs as It Aims for $3 Billion in Cost Savings by 2027
August 22nd 2025

Merck to Cut 6,000 Jobs as It Aims for $3 Billion in Cost Savings by 2027

Don Tracy, Associate Editor
Related Content
Advertisement
CSL to Layoff 15% of Employees, Close 22 US-based Plasma Centers
August 22nd 2025

CSL to Layoff 15% of Employees, Close 22 US-based Plasma Centers

Don Tracy, Associate Editor
Cell and Gene Therapy Check-in 2024
August 22nd 2025

Cell and Gene Therapy Check-in 2024

Miranda Schmalfuhs
AbbVie Latest to Commit to New US Manufacturing Growth Projects, Committing $195 Million to Expand API Capabilities
August 22nd 2025

AbbVie Latest to Commit to New US Manufacturing Growth Projects, Committing $195 Million to Expand API Capabilities

Don Tracy, Associate Editor
Industry Outlook 2022
August 22nd 2025

Industry Outlook 2022

Elaine Quilici Miranda Schmalfuhs
Stephanie J. Creary, Assistant Professor of Management at The Wharton School of The University of Pennsylvania.
August 22nd 2025

How Should BioPharma C-Suites Guide and Support Remaining Employees After Workforce Reductions?

Michael Wong
Merck to Cut 6,000 Jobs as It Aims for $3 Billion in Cost Savings by 2027
August 22nd 2025

Merck to Cut 6,000 Jobs as It Aims for $3 Billion in Cost Savings by 2027

Don Tracy, Associate Editor
About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.